Cotrimoxazole was associated with nearly twice the adverse event rate of fluoroquinolones in a retrospective study of 228 hospitalized men aged 75 or older with urinary tract infections, with acute kidney injury onset occurring at a median of six days post-initiation.

Hemarthrosis affects an estimated 70–80% of people with hemophilia and can progress to permanent joint damage, with pain management presenting a specific medication safety intersection point for pharmacists at the OTC counter and bedside.

US prescription drug expenditures reached $915.2 billion in 2025, with utilization growth rather than price increases accounting for the majority of the 12.7% rise, and clinic-sector spending projected to outpace hospital spending by a factor of three in 2026.

The 2026 KDIGO anemia in CKD guideline replaces two long-standing iron deficiency classifications, endorses proactive high-dose IV iron in maintenance hemodialysis, and provides first-ever positioning guidance on HIF-PHIs, 14 years after the previous version.

Falling Medicaid enrollment under the One Big Beautiful Bill Act is eroding the disproportionate share hospital percentages that determine 340B Drug Pricing Program eligibility at safety-net hospitals, according to a presentation at HOPA 2026.

A clinician review outlined how diagnostic confidence, staging, genetic risk, and imaging features inform patient selection for amyloid-targeting Alzheimer’s therapies.